Back to Search
Start Over
HER1 Vaccine: An autologous EGFR vaccine candidate to treat epithelial tumors
- Source :
- Biotecnología Aplicada, Vol 26, Iss 4, Pp 342-344
- Publisher :
- Elfos Scientiae.
-
Abstract
- The Epidermal Growth Factor Receptor (EGFR) plays an essential role in regulating neoplastic processes. EGFR over-expression in many human epithelial tumors has been correlated with disease progression and bad prognosis. Passive EGFR-directed immunotherapy has been introduced in medical oncology practice, but no active specific approaches have been used. We designed a vaccine candidate based on the extracellular domain (ECD) of human EGFR (HER1), and the homologous vaccine for mice based on murine EGFR. This vaccine candidate uses the Very Small-Sized Proteoliposomes from Neisseria meningitidis (VSSP) and Montanide ISA 51-VG as adjuvants. The autologous vaccine circumvents the tolerance to self EGFR by inducing a specific immune response with an anti-metastatic effect on EGFR+ tumors. The vaccine candidate based on HER1-ECD induced anti-EGFR polyclonal antibodies (PAb) that bind EGFR+ human tumor cell lines from different tissues. These anti-EGFR PAb abrogate ligand-dependent EGFR phosphorylation, provoking the inhibition of tumor cell growth and apoptosis. Preclinical results further encouraged the evaluation of the HER1 vaccine candidate in phase I clinical trials
- Subjects :
- Biotechnology
TP248.13-248.65
Subjects
Details
- Language :
- English, Spanish; Castilian
- ISSN :
- 10272852
- Volume :
- 26
- Issue :
- 4
- Database :
- Directory of Open Access Journals
- Journal :
- Biotecnología Aplicada
- Publication Type :
- Academic Journal
- Accession number :
- edsdoj.0d5a1ed749754134a7cfcea67828a89d
- Document Type :
- article